Company Overview and News

9
Why Is Apple Giving This Tiny Stock A $900 Million Opportunity?

2018-09-16 oilprice - 6
Your license and viewing of our content is subject to the disclosures contained after this article.
SHOP AWSM DSGX DALR BBRY DRLDF DNA.WT.A APH DRRLF CLS APHQF BB DNA

1
Why Is Apple Giving This Tiny Stock A $900 Million Opportunity?

2018-09-13 oilprice - 1
Your license and viewing of our content is subject to the disclosures contained after this article.
DRLDF DNA.WT.A AWSM APH DRRLF APHQF DALR DNA

 
Orion completes acquisition of Dalradian

2018-09-07 globenewswire
TORONTO, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) and Orion Mine Finance (“Orion”) are pleased to announce the completion of the previously announced plan of arrangement (the “Transaction”) and that all required approvals have been obtained and all required conditions satisfied.
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian receives final court order approving arrangement

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has received a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Scythian Biosciences Corp. Announces Andy DeFrancesco as a New Director

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) announced today that it has appointed Andrew DeFrancesco to the Board of Directors effective September 4, 2018.
PXT PARXF AWSM DALR EPS EPSEF DRLDF DNA.WT.A APH DRRLF LHSIF APPCQ APHQF DNA

 
Dalradian shareholders overwhelmingly approve arrangement

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that at a special meeting of its shareholders held today, its shareholders overwhelmingly approved the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian shareholders overwhelmingly approve arrangement

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that at a special meeting of its shareholders held today, its shareholders overwhelmingly approved the previously announced plan of arrangement (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Further to shareholder meeting

2018-08-22 globenewswire
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have both recommended that Dalradian shareholders vote FOR the previously announced transaction (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
ISS and Glass Lewis recommend Dalradian shareholders vote FOR the arrangement

2018-08-22 globenewswire
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have both recommended that Dalradian shareholders vote FOR the previously announced transaction (the “Transaction”) with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian Announces Shareholding

2018-08-17 globenewswire
TORONTO, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA; AIM:DALR) (“Dalradian” or the “Company”) was given notice on 16 August 2018 of a shareholding by LMR Partners LLP (“LMR Partners”). According to the notice, LMR Partners has purchased 11,907,200 common shares and as of 16 August 2018, LMR Partners beneficially held 26,900,000 common shares representing 7.57% of the issued share capital of the Company based on Dalradian’s outstanding shares of 355,493,448.
DRLDF DNA.WT.A DRRLF DALR DNA

 
Notice of GM

2018-08-10 globenewswire
TORONTO, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has mailed its management information circular, related voting materials and letter of transmittal (collectively, the “Meeting Materials”) to its shareholders in connection with the special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian mails shareholder materials for August 31 meeting

2018-08-10 globenewswire
TORONTO, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX: DNA/AIM: DALR) (“Dalradian” or the “Company”) is pleased to announce that it has mailed its management information circular, related voting materials and letter of transmittal (collectively, the “Meeting Materials”) to its shareholders in connection with the special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

 
Dalradian reports Q2 2018 results with cash of $120 million at June 30, 2018

2018-08-09 globenewswire
TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA; AIM:DALR) (“Dalradian” or the “Company”) announces results for the three and six months ended June 30, 2018, including closing cash and cash equivalents of $120 million (all amounts are quoted in Canadian dollars).
DRLDF DNA.WT.A OKSWF DRRLF OR LNSTY OSKGF DALR DNA

 
Dalradian receives interim order setting shareholder meeting for August 31

2018-08-03 globenewswire
TORONTO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA)(AIM:DALR) (“Dalradian” or the “Company”) is pleased to announce that Dalradian has been granted an interim order (the “Interim Order”) authorizing various matters including the holding of a special meeting (the “Meeting”) of Dalradian’s shareholders to consider the previously announced transaction with certain affiliates of Orion Mine Finance (“Orion”).
DRLDF DNA.WT.A OKSWF DRRLF OR OSKGF DALR DNA

7
Junior Gold Explorers Index Near Its 2016 Low

2018-07-30 seekingalpha
Managed money traders are shorting more gold contracts than at any time in the last decade.
MGG MMRGF AOT MEAOF GSV VITFF MAW DALR DRLDF DNA.WT.A AZX PG DRRLF NAK MAI PIRGF WHGOF EQXGF VIT MIMZF MWSNF NDMWF ASOLF ALXDF VGMTD NHK DNA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...